Skip to main content
Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

IMMY17015 / Cellectar / Brea Lipe

Research Question:
Is the study drug, CLR 131, effective for the treatment of multiple myeloma or certain lymphomas?

Basic Study Information

Purpose:
Part A of this study evaluates CLR 131 in patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL) who have been previously treated with standard therapy for their underlying malignancy. Part B (CLOVER-WaM) is a pivotal efficacy study evaluating IV administration of CLR 131 in patients with WM that failed Bruton's tyrosine kinase inhibitors (BTKi).

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT02952508?term=02952508&rank=1
Study Reference #: IMMY17015

Lead Researcher (Principal Investigator)

Lead Researcher:  Brea Lipe

Study Contact Information

Study Coordinator: Tina Bowdish
Phone: +1 585-275-9475
Email: tina_bowdish@urmc.rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Lymphoma

More information about Multiple Myeloma

Return to Search